Bristol Myers Squibb launches new biomedical innovations to improve the lives of patients with inflammatory diseases
-
Last Update: 2020-02-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Bristol Myers Squibb (BMS) and biomotiv jointly announced the launch of anteros pharmaceuticals, which focuses on the development of drugs to treat fibrosis and other inflammatory diseases Anteros is the first Biomedical Company to launch jointly since the two companies entered into a partnership last September Anteros' technology platform was developed by Yale University According to the terms of the agreement between BMS and biomotiv, BMS will provide intellectual property rights, data and reagents for small molecule research drugs for a series of undisclosed mechanisms of action, while biomotiv will provide corresponding technical support and take full responsibility for development by establishing antiros in close cooperation with Yale University BMS will be able to exercise its right to acquire anteros once anteros has identified pre clinical candidates Biomotiv's business focus is to find promising science and technology in the academic community and create R & D companies for them to help researchers drive new technologies The company's Harrington development and development program is a $340 million program designed to support scientists in the discovery and development of breakthrough therapies, a new model to address a series of major challenges in the development of medicine The project, jointly organized by Harrington Development Research Institute and biomotiv, aims to promote drug development from research institutions for the benefit of patients and society In the future, BMS and biomotiv may jointly launch several potential pharmaceutical companies.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.